HomeMarketsSharesStarling Oncology Institute Inc

Trade Starling Oncology Institute Inc - STLN CFD

Market is not available at the momentMarket information is presented
as of 2026-09-30T19:45:32+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.05
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.022207 %
(-$4.44)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02221%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.000015 %
(-$0.00)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.00002%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity10
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close6.5
Open6.46
1-Year Change87.25%
Day's Range6.3 - 6.52

Trade The Oncology Institute, Inc. - TOI

About Oncology Institute Inc

The Oncology Institute, Inc., formerly DFP Healthcare Acquisitions Corp., is an oncology company. The Company manages community-based oncology practices that serve patients at approximately 55 clinic locations across eight markets and four states throughout the United States. The Company’s managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, clinical trial services, programs like outpatient stem cell transplants and transfusions, along with 24/7 patient support. Through the Innovative Clinical Research Institute (ICRI), the Company also provides and manages clinical trial services and research for the benefit of cancer patients. Its services, such as managing clinical trials, palliative care programs and stem cell transplants, are accessed through academic and tertiary care settings. Its managed clinics primarily serve adult and senior cancer patients in markets that have Medicare Advantage (MA) plans.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Oncology Institute Inc revenues was not reported. Net loss increased from $298K to $867K. Higher net loss reflects General and administrative expenses increase from $279K to $4.1M (expense), Interest Income - Non Bank decrease of 70% to $58K (income), General and administrative expenses increase from $53K to $158K (expense).

Latest shares articles

Allianz stock forecast: record H1 profit, Q3 earnings ahead
Allianz is a German insurer whose shares are trading near record levels following record first-half operating profit and reports of a possible €5.8 billion acquisition of AA. Explore third-party ALV targets and technicals. Past performance is not a reliable indicator of future results.
18 hours ago
Assicurazioni Generali stock forecast
Assicurazioni Generali stock forecast: rising bond yields, ECB outlook
Generali is an Italian insurer listed in Milan, with its shares recently trading amid rising eurozone bond yields and wider financial-sector activity in Italy. Explore third-party G price targets and technical analysis. Past performance is not a reliable indicator of future results.
24 hours ago
Amplifon stock forecast
Amplifon stock forecast: H1 growth and margin outlook
Amplifon is an Italian hearing-care company listed on Borsa Italiana. Its pending GN Hearing acquisition remains a key focus as investors assess potential effects on growth, margins and debt. Explore third-party AMP price targets. Past performance is not a reliable indicator of future results.
07:19, 30 September 2026
Uber Technologies stock forecast
Uber Technologies stock forecast: 3,300 job cuts, robotaxi push
Uber is cutting around 3,300 jobs as part of a restructuring, while expanding its autonomous-vehicle partnerships amid growing competition in the robotaxi market. Explore third-party UBER price targets and technical analysis. Past performance is not a reliable indicator of future results.
13:42, 29 September 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready